Podcast Episode
The therapy uses an oncolytic virus called CAN-3110, engineered to replicate exclusively in glioblastoma cells while leaving healthy brain tissue untouched. Once injected, the virus spreads through the tumour, killing cancer cells and triggering an immune response that recruits cytotoxic T cells deep into the tumour environment.
The new research provides mechanistic evidence that the oncolytic virus can overcome this immunosuppressive environment, converting cold tumours into ones that the immune system can recognise and attack.
The study also found that closer proximity of cytotoxic T cells to dying tumour cells was associated with longer patient survival, providing direct evidence that the immune recruitment mechanism translates into therapeutic benefit.
Modified Herpes Virus Helps Immune Cells Attack Deadly Brain Cancer
February 12, 2026
Audio archived. Episodes older than 60 days are removed to save server storage. Story details remain below.
Researchers at Dana-Farber Cancer Institute and Mass General Brigham have shown that a single injection of a genetically engineered herpes virus can recruit cancer-fighting immune cells deep into glioblastoma tumours, nearly doubling survival in some patients. The Phase one trial results, published in Cell, represent a potential breakthrough for a cancer that has resisted immunotherapy for two decades.
A Virus Engineered to Fight Brain Cancer
In a landmark study published in the journal Cell, researchers from Dana-Farber Cancer Institute and Mass General Brigham have demonstrated that a single injection of a genetically modified herpes simplex virus can transform the immune landscape of glioblastoma, one of the deadliest and most treatment-resistant brain cancers.The therapy uses an oncolytic virus called CAN-3110, engineered to replicate exclusively in glioblastoma cells while leaving healthy brain tissue untouched. Once injected, the virus spreads through the tumour, killing cancer cells and triggering an immune response that recruits cytotoxic T cells deep into the tumour environment.
Breaking Through the Cold Tumour Barrier
Glioblastoma has long been classified as a "cold" tumour, meaning it actively suppresses the immune system and prevents cancer-fighting cells from entering. This has made the disease largely immune to the immunotherapies that have revolutionised treatment for cancers like melanoma.The new research provides mechanistic evidence that the oncolytic virus can overcome this immunosuppressive environment, converting cold tumours into ones that the immune system can recognise and attack.
Trial Results Show Extended Survival
In the Phase one trial of 41 patients with recurrent glioblastoma, the results were striking. Patients who already carried antibodies to herpes simplex virus, roughly sixty-six percent of participants, showed a median overall survival of 14.2 months, compared to 7.8 months for those without prior herpes exposure. For context, recurrent glioblastoma typically carries a median survival of just six to nine months.The study also found that closer proximity of cytotoxic T cells to dying tumour cells was associated with longer patient survival, providing direct evidence that the immune recruitment mechanism translates into therapeutic benefit.
A Potential Turning Point
The standard of care for glioblastoma, involving surgery, radiation, and chemotherapy, has remained essentially unchanged for twenty years. With a five-year survival rate below ten percent, glioblastoma remains one of the most devastating cancer diagnoses. This research opens a new avenue that could fundamentally change how the disease is treated, with a follow-up clinical trial already underway.Published February 12, 2026 at 6:53am